PT1133295E - Utilizacao da nicergolina no tratamento da espasticidade - Google Patents

Utilizacao da nicergolina no tratamento da espasticidade

Info

Publication number
PT1133295E
PT1133295E PT99956108T PT99956108T PT1133295E PT 1133295 E PT1133295 E PT 1133295E PT 99956108 T PT99956108 T PT 99956108T PT 99956108 T PT99956108 T PT 99956108T PT 1133295 E PT1133295 E PT 1133295E
Authority
PT
Portugal
Prior art keywords
spasicity
nicergolin
treatment
nicergoline
pathology
Prior art date
Application number
PT99956108T
Other languages
English (en)
Inventor
Michel Dib
Vincent Meininger
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Publication of PT1133295E publication Critical patent/PT1133295E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Soil Working Implements (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Indole Compounds (AREA)
PT99956108T 1998-11-24 1999-11-22 Utilizacao da nicergolina no tratamento da espasticidade PT1133295E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9814794A FR2786101B1 (fr) 1998-11-24 1998-11-24 Utilisation de la nicergoline dans le traitement de la spasticite

Publications (1)

Publication Number Publication Date
PT1133295E true PT1133295E (pt) 2004-01-30

Family

ID=9533131

Family Applications (1)

Application Number Title Priority Date Filing Date
PT99956108T PT1133295E (pt) 1998-11-24 1999-11-22 Utilizacao da nicergolina no tratamento da espasticidade

Country Status (11)

Country Link
US (2) US6380208B2 (pt)
EP (1) EP1133295B1 (pt)
JP (1) JP4936594B2 (pt)
AT (1) ATE248596T1 (pt)
AU (1) AU1278500A (pt)
DE (1) DE69911052T2 (pt)
DK (1) DK1133295T3 (pt)
ES (1) ES2201801T3 (pt)
FR (1) FR2786101B1 (pt)
PT (1) PT1133295E (pt)
WO (1) WO2000030642A1 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2786101B1 (fr) * 1998-11-24 2002-07-05 Aventis Laboratoire Utilisation de la nicergoline dans le traitement de la spasticite
FR2786100B1 (fr) * 1998-11-24 2002-03-01 Aventis Laboratoire Nouvelle application therapeutique de la nicergoline
FR2801793B1 (fr) * 1999-12-01 2003-07-04 Aventis Pharma Sa Association d'une ergoline et de riluzole et son utilisation comme medicament
US6297254B1 (en) 1999-12-01 2001-10-02 Aventis Pharma S. A. Method for the prevention or treatment of a motoneuron disease
DE10053397A1 (de) * 2000-10-20 2002-05-02 Schering Ag Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen
DE10043321B4 (de) * 2000-08-24 2005-07-28 Neurobiotec Gmbh Verwendung eines transdermalen therapeutischen Systems zur Behandlung der Parkinsonschen Krankheit, zur Behandlung und Prävention des prämenstruellen Syndroms und zur Lactationshemmung
DE10064453A1 (de) * 2000-12-16 2002-07-04 Schering Ag Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3228943A (en) 1962-06-11 1966-01-11 Lumilysergol derivatives
YU39278B (en) * 1976-12-22 1984-10-31 Lek Tovarna Farmacevtskih Process for preparing 5-bromo nicotinic acid esters
FR2492258A1 (fr) 1980-10-17 1982-04-23 Pharmindustrie Nouveau medicament a base d'amino-2 trifluoromethoxy-6 benzothiazole
US5668117A (en) * 1991-02-22 1997-09-16 Shapiro; Howard K. Methods of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with previously known medicaments
IT1252163B (it) * 1991-12-03 1995-06-05 Poli Ind Chimica Spa Composizioni farmaceutiche per la neuroprotezione nelle malattie neurologiche di carattere degenerativo o su base ischemica
JP2864885B2 (ja) * 1992-07-02 1999-03-08 田辺製薬株式会社 ニセルゴリン含有経口投与製剤
US5281607B1 (en) * 1992-10-08 1998-05-19 Univ New York Method of using alpha 2-antagonists for the treatment of neurodegenerative diseases
IT1256743B (it) * 1992-12-18 1995-12-15 Giorgio Pifferi Composizioni farmaceutiche a rilascio controllato contenenti nicergolina
US5994294A (en) * 1996-02-02 1999-11-30 Nitromed, Inc. Nitrosated and nitrosylated α-adrenergic receptor antagonist compounds, compositions and their uses
US6294517B1 (en) * 1996-02-02 2001-09-25 Nitromed, Inc. Compositions and kits comprising alpha-adrenergic receptor antagonists and nitric oxide donors and methods of use
AU740758B2 (en) * 1997-10-28 2001-11-15 Vivus, Inc. Treatment of female sexual dysfunction
FR2777781B1 (fr) * 1998-04-24 2004-04-09 Rhone Poulenc Rorer Sa Associations riluzole et l-dopa pour le traitement de la maladie de parkinson
DE19842416A1 (de) * 1998-09-16 2000-04-13 Max Planck Gesellschaft Sekundäre Amine zur Prävention und Therapie von Erkrankungen, die durch Oxidationsprozesse verursacht oder verstärkt werden
FR2785808B1 (fr) * 1998-11-13 2002-12-06 Aventis Laboratoire Association riluzole et alpha-tocopherol
FR2786099B1 (fr) * 1998-11-24 2000-12-29 Aventis Laboratoire Nouvelle application therapeutique de la 1,6-dimethyl-8beta- hydroxymethyl-10alpha-methoxyergoline
FR2786101B1 (fr) * 1998-11-24 2002-07-05 Aventis Laboratoire Utilisation de la nicergoline dans le traitement de la spasticite
FR2786100B1 (fr) * 1998-11-24 2002-03-01 Aventis Laboratoire Nouvelle application therapeutique de la nicergoline
US6297254B1 (en) * 1999-12-01 2001-10-02 Aventis Pharma S. A. Method for the prevention or treatment of a motoneuron disease

Also Published As

Publication number Publication date
US6380208B2 (en) 2002-04-30
JP2003530298A (ja) 2003-10-14
US6713493B2 (en) 2004-03-30
EP1133295A1 (fr) 2001-09-19
DE69911052D1 (de) 2003-10-09
ATE248596T1 (de) 2003-09-15
DK1133295T3 (da) 2003-12-22
US20020013332A1 (en) 2002-01-31
DE69911052T2 (de) 2004-08-19
ES2201801T3 (es) 2004-03-16
EP1133295B1 (fr) 2003-09-03
AU1278500A (en) 2000-06-13
US20020086875A1 (en) 2002-07-04
FR2786101A1 (fr) 2000-05-26
WO2000030642A1 (fr) 2000-06-02
JP4936594B2 (ja) 2012-05-23
FR2786101B1 (fr) 2002-07-05

Similar Documents

Publication Publication Date Title
ATE472325T1 (de) Intrakorporale medikamente zur photodynamischen behandlung von erkrankungen
ATE286895T1 (de) Sulfonyl-pyrrolidinderivate geeignet für die behandlung von neurologischen krankheiten
ATE355293T1 (de) Substituierte 7-aza-(2.2.1)bicycloheptane für die behandlung von krankheiten
NO20000688D0 (no) Anvendelse av lokalt avleverte metallioner for behandling av periodontal sykdom
MXPA03002814A (es) Derivados de morfolin-acetamida para el tratamiento de enfermedades inflamatorias.
EP1274444A4 (en) COMPOUNDS FOR THE TREATMENT OF PSYCHIATRIC DISORDERS OR DISORDERS CAUSED BY THE ABUSE OF PSYCHOACTIVE SUBSTANCES
DE60124576D1 (de) Verbindungen verwendbar für die behandlung von entzündungskrankheiten
IL148071A0 (en) Method for treatment of symptoms of central nervous system disorders
ES2141330T3 (es) Monohidrato de (e)-2'-desoxi-2'-(fluorometileno)citidina.
DK1133295T3 (da) Anvendelse af nicergolin ved behandling af spasticitet
TR200103125T2 (tr) Otizmin iyileştirilmesinde kullanıma yönelik antikonvülsan türevleri.
BR0115882A (pt) Emprego de compostos de 1-fenil-3-dimetilaminopropano no tratamento da incontinência urinária
MA25852A1 (fr) Methode pour le traitement de l'inflammation.
EA200200063A1 (ru) Химера il6ril6 для лечения нейродегенеративных заболеваний
DK1133296T3 (da) Ny terapeutisk anvendelse af nicergolin
NO20005548L (no) Mykobakterieinhibitorer
PT1315496E (pt) Tratamento de desordens inflamatorias
PT1200447E (pt) Oxazinocarbazoles para o tratamento de doencas do snc
ATE343387T1 (de) S-methyl-dihydro-ziprasidon zur behandlung von augenerkrankungen.
PT1235573E (pt) Associacao de riluzole e de gabapentina e sua utilizacao como medicamento no tratamento das doencas motoneuronais
BR9612549A (pt) Método para tratamento de agressão excessiva
DK1133297T3 (da) Ny terapeutisk anvendelse af 1,6-dimethyl-8beta-hydroxymethyl-10alpha-methoxyergolin
UA42301A (uk) Засіб "камілаль" для лікування і профілактики проктологічних захворювань
UA36041A (uk) Спосіб лікування хронічного панкреатиту, ускладненого псевдокістою